Aspirin for High-Risk Pregnancies
(DASH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how different aspirin dosing schedules can assist pregnant women at high risk for preeclampsia and preterm birth. Researchers aim to determine whether taking aspirin once daily or splitting the dose into two is more effective for these conditions. The goal is to find the best way to use aspirin to improve the health of both mothers and babies. Women who are less than 16 weeks pregnant with one baby and have been advised to take aspirin for a high-risk pregnancy may be suitable candidates. As a Phase 1, Phase 2 trial, this research focuses on understanding aspirin's effects in people and measuring its effectiveness, offering participants a chance to contribute to important findings for maternal and infant health.
Will I have to stop taking my current medications?
The trial requires that you do not use any other anticoagulation medications while participating. If you are currently taking such medications, you would need to stop them to join the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that taking low-dose aspirin during pregnancy can be safe for both mothers and babies. Studies indicate that it lowers the risk of preeclampsia, a serious condition during pregnancy. Importantly, low-dose aspirin does not appear to increase the risk of major problems for mothers or newborns. However, higher doses of aspirin might pose risks, such as pregnancy loss. This trial examines different ways to use aspirin to find the safest and most effective method for preventing complications in high-risk pregnancies.12345
Why are researchers excited about this trial's treatment for high-risk pregnancies?
Researchers are excited about these aspirin treatments for high-risk pregnancies because they explore different dosing strategies that could enhance safety and effectiveness. Unlike the standard single daily dose of aspirin, which is commonly used to prevent complications like preeclampsia, this trial includes an experimental split-dose regimen. The split-dose approach, with 81mg of aspirin taken every 12 hours, might maintain more consistent blood levels, potentially offering better protection for the mother and baby. Additionally, the higher daily dose of 162mg aspirin might provide more robust preventive benefits without increasing risks. These innovative dosing strategies aim to optimize aspirin's benefits while minimizing side effects, offering hope for improved outcomes in high-risk pregnancies.
What evidence suggests that aspirin might be an effective treatment for high-risk pregnancies?
This trial will compare two dosing regimens of aspirin for high-risk pregnancies. Studies have shown that aspirin can significantly lower the risk of preeclampsia in pregnant women at high risk. Research indicates that low-dose aspirin reduces the chance of developing preeclampsia by about 17%. Evidence from several trials shows that aspirin does not increase the risk of major bleeding during pregnancy. While the effective dose for preventing preeclampsia can vary, it is important to use a consistent, low dose. These findings suggest that aspirin could improve pregnancy outcomes in high-risk women.14678
Are You a Good Fit for This Trial?
This trial is for pregnant individuals at high risk of complications like preterm birth or preeclampsia. Participants will be those recommended to take aspirin as a preventative measure, but specifics on inclusion and exclusion criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to take either 162mg aspirin daily or 81mg aspirin twice daily
Pharmacokinetic Study
A subset of participants will be evaluated for aspirin pharmacokinetics at two dosing intervals
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Aspirin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Thomas Jefferson University
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator